Novacyt reaches the first close of its financing to support the acquisition of Primerdesign and provides positive business update

Paris, France and Cambridge, UK – 1st April 2016, – Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics, updates the market on its intended acquisition of Primerdesign Ltd (“Primerdesign”) and confirms that it has reached first close in the earlier disclosed €7.0m financing.

Novacyt Primerdesign Acquisition Update PR (1-4-16)